Caseware UK (AP4) 2024.0.164 2024.0.164 Research and experimental development on sciences and engineering 2023-01-01 false 5 false 8 true false 08314520 2023-01-01 2023-12-31 08314520 2022-01-01 2022-12-31 08314520 2023-12-31 08314520 2022-12-31 08314520 c:Director1 2023-01-01 2023-12-31 08314520 c:Director1 2023-12-31 08314520 c:Director4 2023-01-01 2023-12-31 08314520 c:Director4 2023-12-31 08314520 c:Director5 2023-01-01 2023-12-31 08314520 c:Director5 2023-12-31 08314520 c:Director6 2023-01-01 2023-12-31 08314520 c:Director6 2023-12-31 08314520 c:Director7 2023-01-01 2023-12-31 08314520 c:Director7 2023-12-31 08314520 c:Director8 2023-01-01 2023-12-31 08314520 c:Director8 2023-12-31 08314520 c:RegisteredOffice 2023-01-01 2023-12-31 08314520 d:Buildings d:LongLeaseholdAssets 2023-01-01 2023-12-31 08314520 d:PlantMachinery 2023-01-01 2023-12-31 08314520 d:PlantMachinery 2023-12-31 08314520 d:PlantMachinery 2022-12-31 08314520 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 08314520 d:FurnitureFittings 2023-01-01 2023-12-31 08314520 d:FurnitureFittings 2023-12-31 08314520 d:FurnitureFittings 2022-12-31 08314520 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 08314520 d:OfficeEquipment 2023-01-01 2023-12-31 08314520 d:OfficeEquipment 2023-12-31 08314520 d:OfficeEquipment 2022-12-31 08314520 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 08314520 d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 08314520 d:CurrentFinancialInstruments 2023-12-31 08314520 d:CurrentFinancialInstruments 2022-12-31 08314520 d:Non-currentFinancialInstruments 2023-12-31 08314520 d:Non-currentFinancialInstruments 2022-12-31 08314520 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 08314520 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 08314520 d:ShareCapital 2023-12-31 08314520 d:ShareCapital 2022-12-31 08314520 d:RetainedEarningsAccumulatedLosses 2023-01-01 2023-12-31 08314520 d:RetainedEarningsAccumulatedLosses 2023-12-31 08314520 d:RetainedEarningsAccumulatedLosses 2022-01-01 2022-12-31 08314520 d:RetainedEarningsAccumulatedLosses 2022-12-31 08314520 d:RetainedEarningsAccumulatedLosses 2022-01-01 08314520 c:OrdinaryShareClass1 2023-01-01 2023-12-31 08314520 c:OrdinaryShareClass1 2023-12-31 08314520 c:OrdinaryShareClass1 2022-12-31 08314520 c:FRS102 2023-01-01 2023-12-31 08314520 c:Audited 2023-01-01 2023-12-31 08314520 c:FullAccounts 2023-01-01 2023-12-31 08314520 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 08314520 d:WithinOneYear 2023-12-31 08314520 d:WithinOneYear 2022-12-31 08314520 d:BetweenOneFiveYears 2023-12-31 08314520 d:BetweenOneFiveYears 2022-12-31 08314520 d:AcceleratedTaxDepreciationDeferredTax 2023-12-31 08314520 d:AcceleratedTaxDepreciationDeferredTax 2022-12-31 08314520 e:PoundSterling 2023-01-01 2023-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 08314520 Genea Biomedx UK Limited Director's report and financial statements For the Year Ended 31 December 2023
Genea Biomedx UK Limited Company Information
Director | K K Cheng (appointed 18 October 2024)
Registered number | 08314520
Registered office | Office 20, Second Floor
| Innovation House
| Ramsgate Road
| Sandwich
| Kent
| CT13 9FF
Independent auditors | Kreston Reeves Audit LLP
| Statutory Auditor
| 37 St Margaret's Street
| Canterbury
| Kent
| CT1 2TU
Genea Biomedx UK Limited Contents
| Page
Director's report | 1 - 2
Independent auditors' report | 3 - 6
Statement of income and retained earnings | 7
Balance sheet | 8
Notes to the financial statements | 9 - 17
Genea Biomedx UK Limited Director's report For the Year Ended 31 December 2023 The director presents his report and the financial statements for the year ended 31 December 2023.
Director's responsibilities statement
The director is responsible for preparing the Director's report and the financial statements in accordance with applicable law and regulations. Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to: ∙select suitable accounting policies for the company's financial statements and then apply them consistently; ∙make judgements and accounting estimates that are reasonable and prudent; ∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business. The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and to enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Directors
The directors who served during the year were:
Dr Bo Liang (appointed 22 June 2023, resigned 18 October 2024)
K K Cheng (appointed 30 September 2022, resigned 21 June 2023)
H K Hon (appointed 30 September 2022, resigned 21 June 2023)
B Lancken (appointed 30 September 2022, resigned 21 June 2023)
A Low (appointed 30 September 2022, resigned 23 June 2023)
Disclosure of information to auditors
The director at the time when this Director's report is approved has confirmed that: ∙so far as he is aware, there is no relevant audit information of which the company's auditors are unaware, and ∙he has taken all the steps that ought to have been taken as a director in order to be aware of any relevant audit information and to establish that the company's auditors are aware of that information.
Auditors
The audit registration of Kreston Reeves LLP was transferred to Kreston Reeves Audit LLP on 6 October 2025. Kreston Reeves Audit LLP were formally appointed as auditor to the company on 6 October 2025. Under section 487(2) of the Companies Act 2006, Kreston Reeves Audit LLP will be deemed to have been reappointed as auditors 28 days after these financial statements were sent to members or 28 days after the latest date prescribed for filing the accounts with the registrar, whichever is earlier. Page 1
Genea Biomedx UK Limited Director's report (continued) For the Year Ended 31 December 2023
Small companies note
In preparing this report, the director has taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006. This report was approved by the board on 15 January 2026 and signed on its behalf.
K K Cheng Director
Page 2
Genea Biomedx UK Limited Independent auditors' report to the members of Genea Biomedx UK Limited
Qualified opinion
We have audited the financial statements of Genea Biomedx UK Limited (the 'company') for the year ended 31 December 2023, which comprise the Statement of income and retained earnings, the Balance sheet and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice). In our opinion, except for the possible effects of the matter described in the basis for qualified opinion section of our report, the financial statements: ∙give a true and fair view of the state of the company's affairs as at 31 December 2023 and of its profit for the year then ended; ∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and ∙have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for qualified opinion
We were unable to observe the counting of physical inventories held by the company as at the 31 December 2022 & 2023. Following this we were also unable to satisfy ourselves by alternative means concerning the inventory quantities held by the company at 31 December 2022 & 2023, which are included in the balance sheet at a value of £1,687,883 and £652,794 respectively. Consequently we were unable to determine whether any adjustment to this amount was necessary. We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the director's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the director with respect to going concern are described in the relevant sections of this report. Page 3
Genea Biomedx UK Limited Independent auditors' report to the members of Genea Biomedx UK Limited (continued)
Other information
The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' report thereon. The director is responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. As described in the basis for qualified opinion section of our report, we were unable to satisfy ourselves concerning the inventory quantities of £1,687,883 & £652,794 held at 31 December 2022 & 2023 respectively. We have concluded that where the other information refers to the inventory balance or related balances such as cost of sales, it may be materially misstated for the same reason.
Opinion on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit: ∙the information given in the Director's report for the financial year for which the financial statements are prepared is consistent with the financial statements; and ∙the Director's report has been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
Except for the matter described in the basis for the qualifying opinion section of our report, in the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' report. Arising solely from the limitation on the scope of our work relating to inventory, referred to above: ∙we have not obtained all the information and explanations that we considered necessary for the purpose of our audit; and ∙we were unable to determine whether adequate accounting records have been kept. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion: ∙returns adequate for our audit have not been received from branches not visited by us; or ∙the financial statements are not in agreement with the accounting records and returns; or ∙ certain disclosures of directors’ remuneration specified by law are not made.
Responsibilities of directors
As explained more fully in the Director's responsibilities statement set out on page 1, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the director determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the director is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the director either intends to liquidate the company or to cease operations, or have no realistic alternative but to do so. Page 4
Genea Biomedx UK Limited Independent auditors' report to the members of Genea Biomedx UK Limited (continued)
Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below: Capability of the audit in detecting irregularities, including fraud Based on our understanding of the group and industry, and through discussion with the directors and other management (as required by auditing standards), we identified that the principal risks of non-compliance with laws and regulations related to health and safety, anti-bribery and employment law. We considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006, Statement of Recommended Practice, taxation and pension legislation. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit. We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to (examples of risks might include: posting inappropriate journal entries to increase revenue or reduce expenditure, management bias in accounting estimates and judgemental areas of the financial statements. Audit procedures performed by the group engagement team included: ∙Discussions with management and assessment of known or suspected instances of non-compliance with laws and regulations (including health and safety) and fraud. ∙Identifying and assessing the design effectiveness of controls that management has in place to prevent and detect fraud; and ∙Review of cash expenditure to confirm no evidence of personal benefit; and ∙Challenging assumptions and judgements made by management in its significant accounting estimates; and ∙Identifying key contracts and confirming that all required procurement and tendering procedures have been followed; and ∙Checking and reperforming the reconciliation of key control accounts; and ∙Performing analytical procedures to identify any unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and ∙Confirmation of related parties with management, and review of transactions throughout the period to identify any previously undisclosed transactions with related parties outside the normal course of business; and ∙Performing analytical procedures with automated data analytics tools to identify any unusual or unexpected relationships, including related party transactions, that may indicate risks of material misstatement due to fraud; and ∙Reading minutes of meetings of those charged with governance, reviewing internal audit reports and reviewing correspondence with relevant tax and regulatory authorities; and ∙Review of significant and unusual transactions and evaluation of the underlying financial rationale supporting the transactions; and Page 5
Genea Biomedx UK Limited Independent auditors' report to the members of Genea Biomedx UK Limited (continued) Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also: ∙Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. ∙Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the company's internal control. ∙Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the director. ∙Conclude on the appropriateness of the director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditors' report. However, future events or conditions may cause the company to cease to continue as a going concern. ∙Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed. Mark Attwood FCCA (Senior statutory auditor) for and on behalf of Kreston Reeves Audit LLP Statutory Auditor Discovery Park 16 January 2026 Page 6
Genea Biomedx UK Limited Statement of income and retained earnings For the Year Ended 31 December 2023
| 2023 | 2022
| £ | £
Turnover |  | 3,245,659 | 6,413,368
Cost of sales |  | (2,175,717) | (4,655,021)
Gross profit |  | 1,069,942 | 1,758,347
Distribution costs |  | (22,899) | -
Administrative expenses |  | (159,520) | (2,258,052)
Operating profit/(loss) |  | 887,523 | (499,705)
Intercompany write off |  | 1,618,620 | -
Interest receivable and similar income |  | 9,105 | 4,920
Interest payable and expenses |  | (16) | -
Profit/(loss) before tax |  | 2,515,232 | (494,785)
Tax on profit/(loss) |  | - | 56
Profit/(loss) after tax |  | 2,515,232 | (494,729)
Retained earnings at the beginning of the year |  | (8,736,443) | (8,241,714)
Profit/(loss) for the year |  | 2,515,232 | (494,729)
Retained earnings at the end of the year |  | (6,221,211) | (8,736,443)
The notes on pages 9 to 17 form part of these financial statements.
Page 7
Genea Biomedx UK Limited Registered number: 08314520 Balance sheet As at 31 December 2023
|  | 2023 |  | 2022
Note |  | £ |  | £
Fixed assets |  |  |  |  |
Tangible assets | 5 |  | 35,174 |  | 52,220
Current assets |  |  |  |  |
Stocks | 6 | 652,794 |  | 1,687,883 |
Debtors | 7 | 619,133 |  | 893,586 |
Cash at bank and in hand |  | 158,312 |  | 503,205 |
|  | 1,430,239 |  | 3,084,674 |
Creditors: amounts falling due within one year | 8 | (7,617,389) |  | (11,804,102) |
Net current liabilities |  |  | (6,187,150) |  | (8,719,428)
Total assets less current liabilities |  |  | (6,151,976) |  | (8,667,208)
Provisions for liabilities |  |  |  |  |
Deferred tax | 9 |  | (69,234) |  | (69,234)
Net liabilities |  |  | (6,221,210) |  | (8,736,442)
Capital and reserves |  |  |  |  |
Called up share capital | 10 |  | 1 |  | 1
Profit and loss account | 11 |  | (6,221,211) |  | (8,736,443)
|  |  | (6,221,210) |  | (8,736,442)
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements were approved and authorised for issue by the board and were signed on its behalf on 15 January 2026.
K K Cheng
Director
The notes on pages 9 to 17 form part of these financial statements. Page 8
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023
1. | General information
Genea Biomedx UK Limited (the 'company') is a private company limited by shares incorporated in England with the registration number 08314520. The address of the registered office is Office 20, Second Floor Innovation House, Ramsgate Road, Sandwich, Kent, CT13 9FF. 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the company's accounting policies (see note 3). The company's functional and presentational currency is Pounds Sterling. The company's financial statements are presented to the nearest £. The following principal accounting policies have been applied:
| 2.2 | Going concern
In order to meet its day to day working capital requirements the company relies upon support provided by fellow group companies, as and when the need arises. After making enquiries, the directors believe that the company will have adequate resources to continue in operational existence for the foreseeable future. On this basis, the directors consider it appropriate to prepare the financial statements on a going concern basis. While the impact of the COVID-19 virus has been assessed by the directors, so far as reasonably possible, due to its unprecedented impact on the wider economy, it is difficult to evaluate with any certainty the potential outcomes on the company's trade, its customers and suppliers. However, taking into consideration the UK Government's response, the company's planning and group resources, the directors have a reasonable expectation that the company will continue in operational existence for the foreseeable future. Page 9
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023 2.Accounting policies (continued)
| 2.3 | Foreign currency translation
Functional and presentation currency The company's functional and presentational currency is Pounds Sterling. Transactions and balances Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.
| 2.4 | Revenue
Revenue is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised: Sale of goods Revenue from the sale of goods is recognised when all of the following conditions are satisfied: ∙the company has transferred the significant risks and rewards of ownership to the buyer; ∙the company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; ∙the amount of revenue can be measured reliably; ∙it is probable that the company will receive the consideration due under the transaction; and ∙the costs incurred or to be incurred in respect of the transaction can be measured reliably. Rendering of services Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied: ∙the amount of revenue can be measured reliably; ∙it is probable that the company will receive the consideration due under the contract; ∙the stage of completion of the contract at the end of the reporting period can be measured reliably; and ∙the costs incurred and the costs to complete the contract can be measured reliably. Page 10
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023 2.Accounting policies (continued)
| 2.5 | Operating leases: the company as lessee
Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term. Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.
| 2.6 | Finance costs
Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.
| 2.7 | Pensions
Defined contribution pension plan The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations. The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance sheet. The assets of the plan are held separately from the company in independently administered funds.
| 2.8 | Current and deferred taxation
The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the company operates and generates income. Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that: ∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and ∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met. Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Page 11
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023 2.Accounting policies (continued)
| 2.9 | Intangible assets
Development costs are capitalised within intangible assets where they can be identified with a specific product or project anticipated to produce future benefits, and will be amortised when the asset is available for use on a straight line basis over the anticipated life of the benefits arising from the completed product or project.
| 2.10 | Tangible fixed assets
Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method. Depreciation is provided on the following basis:
|  |  |  | Leasehold Improvements | - | 6.67% straight line
|  |  |  | Plant & machinery | - | 12% to 33% straight line
|  |  |  | Fixtures & fittings | - | 20% to 33% straight line
|  |  |  | Office equipment | - | 20% to 33% straight line
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date. Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
| 2.11 | Stocks
Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.
| 2.12 | Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.
| 2.13 | Cash and cash equivalents
Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value. Page 12
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023 2.Accounting policies (continued)
| 2.14 | Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3. | Judgments in applying accounting policies and key sources of estimation uncertainty
The preparation of the financial statements requires the directors to make judgments, estimates and assumptions that can affect the amounts reported for assets and liabilities, and the results for the year. The nature of estimation is such though that actual outcomes could differ significantly from those estimates. The following are the company's key sources of estimation uncertainty: Stock provision Genea Biomedx is a global provider of advanced IVF technologies and solutions, operating in a dynamic healthcare environment where clinical demands and technological standards continually evolve. As a result, it is necessary to assess the recoverability of inventory costs and determine appropriate provisioning. When calculating inventory provisions, management considers the nature and condition of the devices and consumables, as well as applying assumptions regarding anticipated usability and demand for finished products. Stock within Note 6 has been shown net of a £835,076 provision.
4. | Employees
| The average monthly number of employees, including directors, during the year was 5 (2022 - 8).
Page 13
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023
5. | Tangible fixed assets
|  | Plant & machinery | Fixtures & fittings | Office equipment | Total
|  | £ | £ | £ | £
| Cost or valuation |  |  |  |
| At 1 January 2023 | 281,189 | 35,188 | 30,647 | 347,024
| Additions | 29,487 | - | - | 29,487
| At 31 December 2023 | 310,676 | 35,188 | 30,647 | 376,511
| Depreciation |  |  |  |
| At 1 January 2023 | 232,981 | 35,188 | 26,635 | 294,804
| Charge for the year on owned assets | 42,521 | - | 4,012 | 46,533
| At 31 December 2023 | 275,502 | 35,188 | 30,647 | 341,337
| Net book value |  |  |  |
| At 31 December 2023 | 35,174 | - | - | 35,174
| At 31 December 2022 | 48,208 | - | 4,012 | 52,220
Page 14
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023
6. | Stocks
|  |  |  |  | 2023 | 2022
|  |  |  |  | £ | £
| Finished goods | 652,794 | 1,687,883
|  | 652,794 | 1,687,883
7. | Debtors
|  |  |  |  | 2023 | 2022
|  |  |  |  | £ | £
| Due after more than one year |  |
| Other debtors | 118,939 | -
|  | 118,939 | -
| Due within one year |  |
| Trade debtors | 424,109 | 552,221
| Amounts owed by group undertakings | 336 | 310,000
| Other debtors | 52,545 | 28,129
| Prepayments and accrued income | 23,204 | 3,236
|  | 619,133 | 893,586
| The intercompany debtor balance of £310,000 was waived in 2023. This balance was offset against a larger intercompany creditor balance which was cancelled.
8. | Creditors: Amounts falling due within one year
|  |  |  |  | 2023 | 2022
|  |  |  |  | £ | £
| Trade creditors | 40,152 | 9,224
| Amounts owed to group undertakings | 7,321,526 | 11,480,006
| Other taxation and social security | 31,737 | 23,063
| Other creditors | 22,304 | 44,591
| Accruals and deferred income | 201,670 | 247,218
|  | 7,617,389 | 11,804,102
Page 15
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023
9. | Deferred taxation
|  | 2023
|  | £
| At beginning of year | (69,234)
| At end of year | (69,234)
|  |  |  |  | 2023 | 2022
|  |  |  |  | £ | £
| Accelerated capital allowances | (69,234) | (69,234)
|  | (69,234) | (69,234)
10. | Share capital
|  |  |  |  | 2023 | 2022
|  |  |  |  | £ | £
|  | Allotted, called up and fully paid |  |
|  | 1 (2022 - 1) Ordinary share of £1.00 | 1 | 1
11. | Reserves
Profit & loss account This reserve comprises all current and prior period retained profits and losses after deducting any distributions made to the company's shareholders.
12. | Pension commitments
The Company operates a defined contributions pension scheme. The pension cost charge represents contributions payable by the Company to the fund and amounted to £9,982 (2022 - £15,568). Contributions totaling £3,386 (2022 - £2,950) were payable to the fund at the balance sheet date and are included in creditors. Page 16
Genea Biomedx UK Limited Notes to the financial statements For the Year Ended 31 December 2023
13. | Commitments under operating leases
| At 31 December 2023 the company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:
|  |  |  |  | 2023 | 2022
|  |  |  |  | £ | £
| Not later than 1 year | - | 4,378
| Later than 1 year and not later than 5 years | - | 3,283
|  | - | 7,661
14. | Related party transactions
| The company is exempt from disclosing related party transactions with other companies that are wholly owned within the group. All other related party transactions during the current and prior periods, including key management personnel compensation, were made under normal market conditions.
15. | Controlling party
The company is a wholly owned subsidiary of Genea Biomedx Pty Limited, a company incorporated in Australia. Genea Biomedx Pty Ltd is a wholly owned subsidiary of BMX Holdco Pte. Ltd, a company incorporated in Singapore. The consolidated financial statements of BMX Holdco Pte. Ltd, of which the company forms a part, are available on request from the registered office. The ultimate parent undertaking is Aura Group Master Fund VCC, variable capital company incorporated in Singapore.
Page 17